

PRESS RELEASE

innate pharma

INNATE PHARMA FILES ITS 2019 UNIVERSAL REGISTRATION DOCUMENT (*DOCUMENT D'ENREGISTREMENT UNIVERSEL*) AND ITS 2019 ANNUAL REPORT ON FORM 20-F

Marseille, France, April 24, 2020, 4:30 PM CET

Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“**Innate**” or the “**Company**”) today announced the filing of its 2019 Universal Registration Document (*Document d’enregistrement universel*) for the year ended December 31, 2019 with the French market authority “Autorité des Marchés Financiers” (“**AMF**”). It can be consulted and downloaded (in French) on the Company’s website (<https://investors.innate-pharma.com/regulated-information/financial-reports>) and on the AMF’s website (www.amf-france.org).

The Company also announced today the filing of its annual report on Form 20-F for the year ended December 31, 2019 with the United States Securities and Exchange Commission (“**SEC**”). It can be consulted and downloaded on the Company’s website (<https://investors.innate-pharma.com/regulated-information/financial-reports>) and on the SEC’s website (www.sec.gov).

About Innate Pharma:

Innate Pharma S.A. is a commercial stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer.

Innate Pharma’s commercial-stage product, Lumoxiti, in-licensed from AstraZeneca in the US, EU and Switzerland, was approved by the FDA in September 2018. Lumoxiti is a first-in class specialty oncology product for hairy cell leukemia. Innate Pharma’s broad pipeline of antibodies includes several potentially first-in-class clinical and preclinical candidates in cancers with high unmet medical need.


Innate has been a pioneer in the understanding of natural killer cell biology and has expanded its expertise in the tumor microenvironment and tumor-antigens, as well as antibody engineering. This innovative approach has resulted in a diversified proprietary portfolio and major alliances with leaders in the biopharmaceutical industry including Bristol-Myers Squibb, Novo Nordisk A/S, Sanofi, and a multi-products collaboration with AstraZeneca.

Based in Marseille, France, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.

Learn more about Innate Pharma at www.innate-pharma.com

Information about Innate Pharma shares:

ISIN code	FR0010331421
Ticker code	Euronext: IPH Nasdaq: IPHA
LEI	9695002Y8420ZB8HJE29



PRESS RELEASE

innate pharma

Disclaimer:

Neither this press release nor the information contained herein constitute an offer to sell or a solicitation of an offer to buy or subscribe for shares in Innate in any country.

For additional information, please contact:

Investors

Innate Pharma

Danielle Spangler

Tel.: +1 917 499 6240

Danielle.Spangler@innate-pharma.com

Jérôme Marino

Tel.: +33 (0)4 30 30 30 30

investors@innate-pharma.com

Media

Innate Pharma

Tracy Rossin (Global/US)

Tel.: +1 240 801 0076

Tracy.Rossin@innate-pharma.com

ATCG Press

Marie Puvieux (France)

Tel.: +33 (0)9 81 87 46 72

innate-pharma@atcg-partners.com